INBX

Financial Results: Inhibrx Biosciences reported a net loss of $35.3 million for Q3 2025, an improvement from a $43.9 million loss in the same quarter the previous year, with cash reserves of $153.1 million as of September 30, 2025.

Ozekibart Development: The company plans to submit a Biologics License Application (BLA) for its lead drug candidate, Ozekibart, in chondrosarcoma by Q2 2026, following positive Phase 3 trial results showing significant improvements in progression-free survival.

Clinical Trials: Ozekibart is also undergoing Phase I trials for advanced solid tumors, with promising interim data for colorectal cancer and Ewing sarcoma patients. Additionally, Inhibrx is advancing INBRX-106, an immune agonist, in various clinical studies.

Stock Performance: Inhibrx's stock has fluctuated between $10.81 and $86.64 over the past year, closing at $79.13 on November 14, 2025, reflecting a 6.04% increase.

Financial Results: Inhibrx reported a net loss of $35.3 million for Q3 2025, an improvement from a $43.9 million loss in Q3 2024, with cash and cash equivalents totaling $153.1 million as of September 30, 2025.

Clinical Trial Updates: The company announced positive topline results for ozekibart (INBRX-109) in chondrosarcoma, meeting its primary endpoint and showing significant improvements in patient outcomes, with plans to submit a biologics license application to the FDA in Q2 2026.

Research and Development Expenses: R&D expenses decreased to $28.5 million in Q3 2025 from $38.9 million in Q3 2024, attributed to reduced process development activities and a decrease in personnel-related costs.

Corporate Structure: Inhibrx was established as a subsidiary of Inhibrx, Inc. following the sale of INBRX-101 to Sanofi S.A. and has a clinical pipeline that includes ozekibart and INBRX-106, focusing on innovative protein engineering methods.